PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research across a wide range of hematologic diseases at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, which will take place in Atlanta, Georgia, and virtually, from December 11 to 14, 2021. Data from more than 80 company-sponsored studies will be featured, including 23 oral presentations, highlighting key research and development programs in lymphomas, leukemias, multiple myeloma and myeloid diseases, and showcasing our commitment to delivering transformative medicines across major hematologic diseases.

Key data being presented by Bristol Myers Squibb and its partners at the 2021 ASH Annual Meeting and Exposition include:

Our presence at ASH continues our longstanding commitment to hematology and underscores the potential of our innovative research platforms to deliver meaningful, new treatment options for people with unmet needs living with hematologic diseases, said Samit Hirawat, M.D., executive vice president, chief medical officer, global drug development, Bristol Myers Squibb. These data reinforce our progress in advancing transformative research across a wide range of hematologic malignancies including multiple myeloma, lymphoma, and myeloid diseases.

SelectedBristol Myers Squibb studies at the 63rd ASH Annual Meeting and Exposition include:

Abstract Title

Author

Presentation Type/#

Session Title

Session Date/Time

Acute Myeloid Leukemia

Prognostic Impact of NPM1 and FLT3 Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance

Hartmut Dhner

Oral

Abstract #804

617. Acute Myeloid Leukemia: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: New options of risk assessment and prediction of therapy response in AML

Monday, December 13,

5:45 PM

Long-term Overall Survival (OS) with Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Updated Results from the Phase 3 QUAZAR AML-001 Trial

Andrew Wei

Oral

Abstract #871

615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Updates in treatment for high-risk AML

Monday, December 13,

6:15 PM

Beta Thalassemia

Luspatercept Redistributes Body Iron to the Liver in Transfusion-Dependent-Thalassemia (TDT) During Erythropoietic Response

Maciej Garbowski

Oral Abstract

#761

102. Iron Homeostasis and Biology: Disorders of Iron and Heme and Novel Treatments

Monday, December 13,

5:30 PM

Luspatercept Improves Health-Related Quality of Life (HRQoL) Symptoms and RBC Transfusion Burden in Patients with Non-Transfusion-Dependent -thalassemia (NTDT) in the BEYOND Trial

Antonis Kattamis

Poster Abstract #3081

112. Thalassemia and Globin Gene Regulation: Poster III

Monday, December 13,

6:00 - 8:00 PM

Graft vs. Host Disease

Overall Survival of Patients Treated with Abatacept in Combination with a Calcineurin Inhibitor and Methotrexate After Allogeneic Hematopoietic Stem Cell Transplantation - Analysis of the Center for International Blood and Marrow Transplant Research Database

Leslie Kean

Poster Abstract #3912

722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster III

Monday, December 13, 6:00 8:00 PM

Lymphoma

Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed by Autologous Stem Cell Transplantation (ASCT) as Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 TRANSFORM Study

Manali Kamdar

Oral Abstract

#91

704. Cellular Immunotherapies: Cellular Therapies for Lymphomas

Saturday, December 11,

9:30 AM

Ruxolitinib Plus Nivolumab in Patients with R/R Hodgkin Lymphoma after Failure of Check-Point Inhibitors: Preliminary Report on Safety and Efficacy

Veronika

Bachanova

Oral Abstract

#230

624. Hodgkin Lymphomas and T/NK cell Lymphomas: Hodgkin Lymphoma Clinical Trials

Hematology Disease Topics & Pathways:

Clinical Trials

Saturday, December 11, 2:15 PM

Nivolumab First-Line Therapy for Elderly Hodgkin Lymphoma Patients: a LYSA Phase II Study

Julien Lazarovici

Oral Abstract

#232

624. Hodgkin Lymphomas and T/NK cell Lymphomas: Hodgkin Lymphoma Clinical Trials

Saturday, December 11, 2:45 PM

OUTREACH: Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) Administered as Inpatient (Inpt) or Outpatient (Outpt) Treatment in the Nonuniversity Setting in Patients (Pts) with R/R Large B-Cell Lymphoma (LBCL)

John Godwin

Poster Abstract

#1762

704. Cellular Immunotherapies: Clinical: Poster I

Saturday, December 11,

5:30 7:30 PM

Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance

Franck Morschhauser

Poster Abstract

#2417

623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II

Sunday, December 12,

6:00 - 8:00 PM

Original post:
Bristol Myers Squibb to Highlight More than 80 Abstracts at ASH 2021 Demonstrating Strength of Innovative Therapeutic Platforms Improving Outcomes for...